Webinar

Precision Execution Of Bispecifics At Scale From Design To Delivery

Source: Lonza
GettyImages-1441662840-lab-team-communication-collaboration

Bispecific antibodies offer advantages as therapeutic modalities, including precise targeting and increased efficacy. However, production in CHO cells can present challenges that affect COGs, such as incorrect antibody chain pairing. In this presentation, we describe bYlok®, a new technology that promotes highly efficient heavy-light chain dimerization, and show some case studies where bYlok® plus other tools in the Lonza GS® toolbox can be combined to improve bsAb expression.

access the Webinar!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Lonza